Pembrolizumab Induced Calcitriol-Mediated Hypercalcemia. (6th January 2023)

• Record Type: Journal Article
• Authors: Oommen, Tiffany T.; Sun, Kelly; Barranco-Trabi, Javier; Berenberg, Jeffrey; Kim, Myungjin
• Other Names: Pham Phuong Chi Academic Editor.
• Is Part Of: Case reports in nephrology. Volume 2023(2023)
• Publication Date: 2023-01-06
• Subjects: Nephrology -- Periodicals; Kidneys -- Diseases -- Periodicals; Nephrology; Kidneys -- Diseases; Nephrology; Periodicals; Electronic journals; Periodicals; 616.61
• DOI: 10.1155/2023/9160326
• Languages: English
• ISSNs: 2090-6641

Abstract

Abstract : PD-1/PD-L1 inhibitors such as pembrolizumab have radically improved the prognosis for many patients with advanced malignancies. Although revolutionary, its use can be complicated and limited by various immune-related adverse effects. Effective management depends on early recognition and prompt intervention. Herein, we describe a unique syndrome of hypercalcemia, with associated acute renal injury and hypoxic respiratory failure that was responsive to corticosteroids suggestive of immunotoxicity from pembrolizumab.